交替使用非格司亭生物类似药EP2006与参照药预防乳腺癌化疗后严重中性粒细胞减少的III期研究
该III期随机双盲研究在218例接受TAC方案化疗的乳腺癌患者中,比较交替使用非格司亭生物类似药EP2006与参照药非格司亭(每周期互换)与全程使用参照药的疗效和安全性。结果显示,第2-6周期发热性中性粒细胞减少发生率两组分别为0%和3.4%,差异为-3.4%(95%CI -9.65%至4.96%),满足非劣效性;安全性和免疫原性无临床意义差异。
要点
- 交替使用EP2006与参照非格司亭在预防发热性中性粒细胞减少方面非劣效于全程参照药。
- 两组感染发生率、住院率及非格司亭相关不良事件发生率相似。
- 未检测到中和抗体,免疫原性无差异。
核心结论
- 交替使用参照非格司亭与生物类似药EP2006在疗效、安全性和免疫原性方面均无临床意义差异。
研究设计与样本
- III期随机双盲注册研究,共纳入218例接受(新)辅助TAC方案化疗的乳腺癌患者。
- 患者按1:1:1:1随机分为四组:两组全程使用单一产品(生物类似药或参照药),两组每周期交替使用(生物类似药后参照药或反之)。
- 主要分析比较第2-6周期交替组(n=109)与全程参照药组(n=52)的疗效和安全性。
主要发现
- 第2-6周期发热性中性粒细胞减少发生率:参照药组0%,交替组3.4%(n=3),差异-3.4%(95%CI -9.65%至4.96%),满足非劣效性。
- 感染发生率:交替组9.3%,参照药组9.9%。
- 因发热性中性粒细胞减少住院:仅交替组1例(第6周期)。
- 非格司亭相关不良事件(所有周期):交替组42.1%,参照药组39.2%;肌肉骨骼/结缔组织疾病:35.5% vs 39.2%,包括骨痛30.8% vs 33.3%。
- 未检测到中和抗体。
关键数值与推荐
- 非劣效性界值为-15%(95%CI下限需高于-15%)。
- 发热性中性粒细胞减少发生率差异-3.4%(95%CI -9.65%至4.96%),满足非劣效性。
临床怎么用
- 在乳腺癌化疗患者中,交替使用参照非格司亭与生物类似药EP2006不影响疗效和安全性,支持临床实践中互换使用。
局限性
- 样本量较小(交替组109例,参照药组52例),可能影响罕见不良事件的检测。
- 研究仅针对乳腺癌TAC方案化疗患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2015, the biosimilar filgrastim EP2006 became the first biosimilar approved by the US Food and Drug Administration for commercial use in the United States, marketed as Zarxio® (Sandoz). This phase III randomised, double-blind registration study in patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy (TAC; docetaxel + doxorubicin + cyclophosphamide) compares reference filgrastim, Neupogen® (Amgen), with two groups receiving alternating treatment with reference and biosimilar every other cycle. PATIENTS AND METHODS: A total of 218 patients receiving 5 µg/kg/day filgrastim over six chemotherapy cycles were randomised 1: 1: 1: 1 into four arms. Two arms received only one product, biosimilar or reference (unswitched), and two arms (switched) received alternating treatments every other cycle (biosimilar then reference or vice versa over six cycles). Since the switch occurred from cycle 2 onwards, this analysis compared pooled switched groups to the unswitched reference group for efficacy during cycles 2-6. Safety was also assessed. Non-inferiority in febrile neutropenia (FN) rates between groups for cycles 2-6 was shown if 95% were within a pre-defined margin of - 15%. RESULTS: A total of 109 patients switched treatment, and 52 patients received reference in all cycles. Baseline characteristics were similar between groups. The incidence of FN was 0% (reference) versus 3.4% (n = 3, switched) across cycles 2-6, with a difference of - 3.4% (95% confidence interval: -9.65% to 4.96%), showing non-inferiority. Infections occurred in 9.3% (switched) versus 9.9% (reference). Hospitalisation due to FN was low (one patient in cycle 6; switched). Adverse events related to filgrastim were reported in 42.1% (switched) versus 39.2% (reference) (all cycles). Musculoskeletal/connective tissue disorders related to filgrastim occurred in 35.5% (switched) versus 39.2% (reference) (all cycles), including bone pain (30.8% versus 33.3%). No neutralising antibodies were detected. CONCLUSIONS: There were no clinically meaningful results regarding efficacy, safety or immunogenicity when switching from reference to biosimilar filgrastim/EP2006, or vice versa.
引用
- Blackwell K, Gascon P, Krendyukov A, et al. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2018. PMID: 29091995. doi:10.1093/annonc/mdx638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。